Printer Friendly

Lorus Therapeutics patents to protect lead anticancer target.

Lorus Therapeutics, Inc. (Toronto, Canada) has obtained a patent to protect the company's intellectual property involving a lead anticancer target, the R1 component of ribonucleotide reductase. This patent broadens the protection that Lorus obtained in a patent granted by the United States Patent and Trademark Office in September 2000.

"The two components of ribonucleotide reductase, R1 and R2, are integral to our antisense technology platform and are being used to develop very promising anticancer drugs that are currently in clinical trials," said Dr. Jim Wright, CEO, Lorus Therapeutics. "This patent along with two other patents protecting the R1 and R2 targets already granted in the United States, provide strong and broad protection for a key portion of Lorus's anticancer drug development program, which includes GTI-2040 and GTI- 2501, two drugs in clinical trials."

Ribonucleotide reductase is an essential part of the process that converts ribonucleotides to deoxyribonucleotides, which are required for DNA replication and cell proliferation. Inhibition of ribonucleotide reductase by antisense drugs would lead to depletion of the supply of deoxyribonucleotides to tumor cells, and dramatic reduction in tumor growth. GTI-2040 and GTI-2501 are antisense drugs directed at the R2 and R1 subunits of ribonucleotide reductase, respectively.

GTI-2040, Lorus's most advanced antisense drug, is currently in a phase II clinical trial for the treatment of kidney cancer in combination with capecitabine and is moving into multiple phase II clinical trials for other cancer types.

GTI-2501 is being assessed as a monotherapy in a phase I clinical trial against a variety of advanced cancers. Following successful completion of this clinical trial, Lorus is planning a phase II development strategy to fully investigate the anti-tumor effectiveness of GTI-2501.

Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an active acquisition and in-licensing program, Lorus is building a portfolio of promising anti-cancer drugs. Late-stage clinical developments and marketing will be done in cooperation with strategic pharmaceutical partners.

Lorus Therapeutics, Inc.

+1-416-798-1200

www.lorusthera.com
COPYRIGHT 2003 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:ribonucleotide reductase
Publication:BIOTECH Patent News
Geographic Code:1CANA
Date:Mar 1, 2003
Words:364
Previous Article:Boston invention covers treament for arthritis patients.
Next Article:Genzyme Biosurgery, Excigen collaborate in developing gene therapy for cardiac arrhythmia.
Topics:


Related Articles
LORUS' VIRULIZIN EFFECTIVE AGAINST PANCREATIC TUMORS.
Genta licenses antisense technology to Epigenesis.
Is there a class IV, manganese dependent ribonucleotide reductase?
Lorus obtains United States tumor suppression patent.
Daewoong obtains United States patent.
FDA APPROVES LORUS/NCI GTI-2040 PHASE II CLINICAL TRIAL.
NUCHEM ALLOWED MOLECULES PATENT BY EUROPEAN PATENT OFFICE.
Lorus Therapeutics' intellectual property portfolio strengthened by cancer patent.
LORUS SIGNS VIRULIZIN SUPPLY PACT WITH BIOVECTRA.
LORUS THERAPEUTICS REPORTS 2ND QTR '06 NET LOSS OF $5.1 MIL.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters